Browse Market Research Report @ http://www.transparencymarketresearch.com/hemostasis-diagnostics-market.html
Rising global prevalence of hemophilia A and B, the most common inherited bleeding disorders, significant surge in a variety of surgeries and trauma patients, and increasing use of recombinant products are the factors likely to drive the hemostasis diagnostics market in the near future. The rapid rate of introduction of cost effective and biodegradable products in the global market is also aiding the growth of the market. Growth across cost-sensitive emerging markets is essentially due to easy availability of cost-effective products. However, saturation of the global hemostasis market and high cost structures of advanced hemostasis products are hampering the growth of the market.
The hemostasis diagnostics market has been segmented based on product type, end-user, and region. Based on product type, the hemostasis diagnostics market has been segmented into analyzers, reagents, and consumables. Analyzers can be further segmented into fully automated analyzers and semi-automated analyzers. Accuracy of hematology analyzers has been enhanced by automation of systems and use of cell surface marker labels. Automated analyzers function by sampling the blood and classifying cell populations by quantification and description. This may be carried out using both electrical and optical techniques. Sophisticated hematology blood cell analyzers are enabling precise disease diagnosis at an early stage. Fully-automated systems compact in size, easy to use, providing networking solutions, and efficient data management have increased adoption of hematology analyzers. In terms of end-user, the hemostasis diagnostics market has been segmented into hospitals, clinical testing laboratories, research & academic institutes, and others.
Hematology instruments and reagents continue to maintain strong position in the health care industry. Market players are making significant investment in product development to offer user-friendly, more sophisticated, efficient, and accurate analyzers to meet the demands of hospitals and clinics. Automated systems play a crucial role in transfusion medicines and facilitate screening of blood donors as well as quality control of blood products.
Geographically, the hemostasis diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global hemostasis diagnostics market owing to the rising installed instrument base leading to higher sales of reagents and support services in the U.S. Beckman Coulter is the market leader in hematology analyzers in the U.S.; however, it faces continuous competition from Sysmex products. The hemostasis diagnostics market in Europe is expected to be driven by steady rise in geriatric population which would boost demand for hemostasis. The vast and continuously rising set of under-served population suffering from bleeding disorders such as hemophilia, especially across developing economies such as India, is expected to boost the adoption of hemostasis products in Asia Pacific. Emerging markets such as India, China, and Brazil are registering significant growth due to increasing population, rise in health care expenditure and higher affordability, economic development, and improving technical capabilities by these countries.
For more information on this report, fill the form @ http://bit.ly/2mN331c
Major players operating in the hemostasis diagnostics market include Abbott Laboratories, Becton, Dickinson and Company, Grifols, S.A, Alere, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers, and Beckman Coulter, Inc.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
No comments:
Post a Comment